Veru (VERU)

Executive Summary

Veru Inc. is a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases. Its lead candidate, enobosarm, is a selective androgen receptor modulator (SARM) designed to preserve muscle mass during GLP-1 therapy for weight loss. A Phase 2 trial of enobosarm combined with semaglutide completed in August 2025, and a new Phase 2 trial (NCT07446998) evaluating enobosarm plus Wegovy for obesity commenced in March 2026. The company also develops sabizabulin, an oral anti-inflammatory for atherosclerotic coronary artery disease. Despite several terminated pipeline programs, Veru's strategic pivot to muscle preservation in GLP-1 users addresses a large underserved market. However, the company's small market cap (~$37M) and early-stage data create high risk. Key upcoming catalysts include the release of data from the completed Phase 2 trial, interim results from the ongoing study, and potential partnership or licensing interest from larger metabolic disease players.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 Data Readout for Enobosarm + Semaglutide (Muscle Preservation)60% success
• Q1 2027Interim Data from Enobosarm + Wegovy Phase 2 Trial (Obesity)40% success
• H2 2026Potential Partnership or Licensing Deal for Enobosarm30% success